Inside informationEnglish
Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Sanofi
- Filed
- 17/02/2026, 12:00
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 115122_20260217